Skip to content

Story: HIV Short Film, “Right To Try”

  • Dorrit Walsh

December 2021 Update, June 2022: The purported researcher responsible for the experiment described in this film, Serhat Gumrukcu, was indicted for murder-for-hire at the end of May 2022. The case is ongoing. In parallel, two independent investigations by financial media…

Read more

Unique Barriers to COVID-19 Vaccine Access for Black Communities

  • Dorrit Walsh
On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.
Read more
Cover image of A Landscape Analysis of HIV Cure-Related Clinical Research in 2019–Community Survey

A Landscape Analysis of HIV Cure-Related Clinical Research in 2019

  • Dorrit Walsh
In 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing. TAG conducted this second survey in the fall of 2019 to track any changes over time and provide updated information on status of the field.
Read more

Statement on Human Challenge Studies for COVID-19 Vaccine Development

  • Dorrit Walsh
Two recent developments have brought renewed publicity to proposals to conduct human challenge studies to test COVID-19 vaccine candidates: an open letter from the organization 1DaySooner and media reports that Adrian Hill’s Oxford University research group is planning a challenge study, taking advantage of the lack of regulatory oversight of human challenge experiments in the United Kingdom.
Read more

Treatment Action Group Statement on New HIV Remission Case Report at AIDS2020

  • Dorrit Walsh
Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
Read more
Back To Top